Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins

Virology

Volumn 394, Issue 1, 2009, Pages 91-98

  Gao, Feng ^a   Scearce, Richard M ^a   Alam, S Munir ^a   Hora, Bhavna ^a   Xia, Shimao ^a   Hohm, Julie E ^a   Parks, Robert J ^a   Ogburn, Damon F ^a   Tomaras, Georgia D ^a   Park, Emily ^b   Lomas, Woodrow E ^b   Maino, Vernon C ^b   Fiscus, Susan A ^c   Cohen, Myron S ^c   Moody, M Anthony ^a   Hahn, Beatrice H ^d   Korber, Bette T ^e   Liao, Hua xin ^a   Haynes, Barton F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BD BIOSCIENCES   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Cross reactivity; Envelope glycoprotein; HIV 1; Monoclonal antibody; Subtype

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 16H3; MONOCLONAL ANTIBODY 3B3; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; SURFACE PLASMON RESONANCE; VIRION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV-1; MICE; MICE, INBRED BALB C; PROTEIN BINDING; SIMIAN IMMUNODEFICIENCY VIRUS; SURFACE PLASMON RESONANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 70350134276     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.07.041     Document Type: Article

References (47)

1. Abacioglu Y.H., Fouts T.R., Laman J.D., Claassen E., Pincus S.H., Moore J.P., Roby C.A., Kamin-Lewis R., and Lewis G.K. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res. Hum. Retroviruses 10 4 (1994) 371-381
2. Alam S.M., McAdams M., Boren D., Rak M., Scearce R.M., Gao F., Camacho Z.T., Gewirth D., Kelsoe G., Chen P., and Haynes B.F. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178 7 (2007) 4424-4435
3. Alam S.M., Scearce R.M., Parks R.J., Plonk K., Plonk S.G., Sutherland L.L., Gorny M.K., Zolla-Pazner S., Vanleeuwen S., Moody M.A., Xia S.M., Montefiori D.C., Tomaras G.D., Weinhold K.J., Karim S.A., Hicks C.B., Liao H.X., Robinson J., Shaw G.M., and Haynes B.F. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82 1 (2008) 115-125
4. Beddows S., Franti M., Dey A.K., Kirschner M., Iyer S.P., Fisch D.C., Ketas T., Yuste E., Desrosiers R.C., Klasse P.J., Maddon P.J., Olson W.C., and Moore J.P. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360 2 (2007) 329-340
5. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., Kajumo F., Anselma D.J., Maddon P.J., Olson W.C., and Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74 2 (2000) 627-643
6. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 23 (2004) 13232-13252
7. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 5187 (1994) 1024-1027
8. Chakrabarti B.K., Kong W.P., Wu B.Y., Yang Z.Y., Friborg J., Ling X., King S.R., Montefiori D.C., and Nabel G.J. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76 11 (2002) 5357-5368
9. Chan- Hui P.-Y., Wagner D., Frey S., Ward C., Phung P., Wrin T., Olsen O., Grondin R., Fitch A., Hammond P., Mosley B., Mitcham J., Fling S., Joako W., Omosa G., Farah B., Team P.G., Burton D., Koff W., Moyle M., and Phogat S. Isolation of HIV-1 neutralizing human monoclonal antibodies from memory B cell repertoire using short term culture and high-throughput neutralization screen. Prevention of HIV/AIDS: Keystone Symposia, Abstract (2009) # 119
10. Crooks E.T., Moore P.L., Franti M., Cayanan C.S., Zhu P., Jiang P., de Vries R.P., Wiley C., Zharkikh I., Schulke N., Roux K.H., Montefiori D.C., Burton D.R., and Binley J.M. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366 2 (2007) 245-262
11. Derby N.R., Gray S., Wayner E., Campogan D., Vlahogiannis G., Kraft Z., Barnett S.W., Srivastava I.K., and Stamatatos L. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens. Virology 366 2 (2007) 433-445
12. Gao F., Bailes E., Robertson D.L., Chen Y., Rodenburg C.M., Michael S.F., Cummins L.B., Arthur L.O., Peeters M., Shaw G.M., Sharp P.M., and Hahn B.H. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397 6718 (1999) 436-441
13. Gao F., Bhattacharya T., Gaschen B., Taylor J., Moore J.P., Novitsky V., Yusim K., Lang D., Foley B., Beddows S., Alam M., Haynes B., Hahn B.H., and Korber B. Consensus and ancestral state HIV vaccines (letter). Science 299 (2003) 1517-1518
14. Gao F., Weaver E.A., Lu Z., Li Y., Liao H.X., Ma B., Alam S.M., Scearce R.M., Sutherland L.L., Yu J.S., Decker J.M., Shaw G.M., Montefiori D.C., Korber B.T., Hahn B.H., and Haynes B.F. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J. Virol. 79 2 (2005) 1154-1163
15. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B.H., Bhattacharya T., and Korber B. Diversity considerations in HIV-1 vaccine selection. Science 296 5577 (2002) 2354-2360
16. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., Heyward W.L., Jobes D.V., Popovic V., Self S.G., Sinangil F., Burke D., and Berman P.W. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191 5 (2005) 666-677
17. Gilljam G., Svensson A., Ekstrom A., and Wahren B. Immunological responses to envelope glycoprotein 120 from subtypes of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 15 10 (1999) 899-907
18. Gorny M.K., Stamatatos L., Volsky B., Revesz K., Williams C., Wang X.H., Cohen S., Staudinger R., and Zolla-Pazner S. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79 8 (2005) 5232-5237
19. Hahn B.H., Shaw G.M., De Cock K.M., and Sharp P.M. AIDS as a zoonosis: scientific and public health implications. Science 287 5453 (2000) 607-614
20. Hemelaar J., Gouws E., Ghys P.D., and Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20 16 (2006) W13-23
21. Kuiken C.L., Leitner T., Foley B., Hahn B.H., Marx P.A., McCutchan F., Wolinksy S., and Korber B. "HIV sequence compendium 2008." Theoretical Biology and Biophysics Group (2008), Los Alamos National Laboratory, Los Alamos, New Mexico
22. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 6686 (1998) 648-659
23. Lal R.B., Chakrabarti S., and Yang C. Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy & vaccine development. Indian J. Med. Res. 121 4 (2005) 287-314
24. Lee S.A., Orque R., Escarpe P.A., Peterson M.L., Good J.W., Zaharias E.M., Berman P.W., Sheppard H.W., and Shibata R. Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates. Vaccine 20 3-4 (2001) 563-576
25. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
26. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T., Hunter E., Hahn B.H., and Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80 23 (2006) 11776-11790
27. Li Y., Svehla K., Mathy N.L., Voss G., Mascola J.R., and Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J. Virol. 80 3 (2006) 1414-1426
28. Liao H.X., Sutherland L.L., Xia S.M., Brock M.E., Scearce R.M., Vanleeuwen S., Alam S.M., McAdams M., Weaver E.A., Camacho Z., Ma B.J., Li Y., Decker J.M., Nabel G.J., Montefiori D.C., Hahn B.H., Korber B.T., Gao F., and Haynes B.F. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353 2 (2006) 268-282
29. Lin G., and Nara P.L. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr. HIV Res. 5 6 (2007) 514-541
30. Moore J.P., Cao Y., Leu J., Qin L., Korber B., and Ho D.D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70 1 (1996) 427-444
31. Moore J.P., McCutchan F.E., Poon S.W., Mascola J., Liu J., Cao Y., and Ho D.D. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J. Virol. 68 12 (1994) 8350-8364
32. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X., Binley J.M., Zhang M.Y., Sidorov I.A., Broder C.C., Robinson J., Parren P.W., Burton D.R., and Dimitrov D.S. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad Sci. U.S.A. 99 10 (2002) 6913-6918
33. Osmanov S., Pattou C., Walker N., Schwardlander B., and Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquir. Immune. Defic. Syndr. 29 2 (2002) 184-190
34. Palker T.J., Scearce R.M., Miller S.E., Popovic M., Bolognesi D.P., Gallo R.C., and Haynes B.F. Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV. J. Exp. Med. 159 4 (1984) 1117-1131
35. Peeters M., Toure-Kane C., and Nkengasong J.N. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 17 18 (2003) 2547-2560
36. Reeves J.P., Lo C.Y., Klinman D.M., and Epstein S.L. Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates. Hybridoma 14 3 (1995) 235-242
37. Robertson D.L., Anderson J.P., Bradac J.A., Carr J.K., Foley B., Funkhouser R.K., Gao F., Hahn B.H., Kalish M.L., Kuiken C., Learn G.H., Leitner T., McCutchan F., Osmanov S., Peeters M., Pieniazek D., Salminen M., Sharp P.M., Wolinsky S., and Korber B. HIV-1 nomenclature proposal. Science 288 5463 (2000) 55-56
38. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., and Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76 14 (2002) 7293-7305
39. Srivastava I.K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., Martin L., Vita C., Zhu P., Roux K.H., Vojtech L., Montefiori D.C., Donnelly J., Ulmer J.B., and Barnett S.W. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol. 77 20 (2003) 11244-11259
40. Sugiura W., Broder C.C., Moss B., and Earl P.L. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Virology 254 2 (1999) 257-267
41. Taylor B.S., Sobieszczyk M.E., McCutchan F.E., and Hammer S.M. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358 15 (2008) 1590-1602
42. Tobin G.J., Trujillo J.D., Bushnell R.V., Lin G., Chaudhuri A.R., Long J., Barrera J., Pena L., Grubman M.J., and Nara P.L. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26 49 (2008) 6189-6199
43. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas III C.F., Burton D.R., Ho D.D., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69 11 (1995) 6609-6617
44. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 2 (1996) 1100-1108
45. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 46 6 (2002) 1896-1905
46. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., and Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393 6686 (1998) 705-711
47. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 22 (2001) 10892-10905